Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
| ARQT Stock | USD 13.71 0.63 4.82% |
Slightly above 55% of Arcutis Biotherapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading Arcutis Biotherapeutics stock suggests that some investors are interested at this time. Arcutis Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, Arcutis Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
Arcutis |
Quarterly investor conference call and webcast is scheduled for Wednesday, November 6 at 430 p.m. ETArcutis management will also participate in the...
Read at globenewswire.com
 |
Arcutis Biotherapeutics Fundamental Analysis
We analyze Arcutis Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcutis Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcutis Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Arcutis Biotherapeutics is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Arcutis Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcutis Biotherapeutics stock to make a market-neutral strategy. Peer analysis of Arcutis Biotherapeutics could also be used in its relative valuation, which is a method of valuing Arcutis Biotherapeutics by comparing valuation metrics with similar companies.
Peers
Arcutis Biotherapeutics Related Equities
| ABOS | Acumen Pharmaceuticals | 7.36 | ||||
| DSGN | Design Therapeutics | 6.37 | ||||
| TERN | Terns Pharmaceuticals | 4.94 | ||||
| BOLT | Bolt Biotherapeutics | 3.92 | ||||
| ERAS | Erasca | 1.58 | ||||
| DAWN | Day One | 1.14 | ||||
| AMLX | Amylyx Pharmaceuticals | 0.87 | ||||
| APLS | Apellis Pharmaceuticals | 0.86 | ||||
| CHRS | Coherus BioSciences | 0.76 | ||||
| MIRM | Mirum Pharmaceuticals | 2.63 | ||||
| GLUE | Monte Rosa | 2.81 | ||||
| SPRO | Spero Therapeutics | 3.33 | ||||
| INZY | Inozyme Pharma | 3.70 | ||||
| XFOR | X4 Pharmaceuticals | 3.92 |
Additional Tools for Arcutis Stock Analysis
When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.